A Global Review on Short Peptides: Frontiers and Perspectives.
Apostolopoulos V, Bojarska J, Chai TT, Elnagdy S, Kaczmarek K, Matsoukas J, New R, Parang K, Lopez OP, Parhiz H, Perera CO, Pickholz M, Remko M, Saviano M, Skwarczynski M, Tang Y, Wolf WM, Yoshiya T, Zabrocki J, Zielenkiewicz P, AlKhazindar M, Barriga V, Kelaidonis K, Sarasia EM, Toth I. · 2021
Read A Global Review on Short Peptides: Frontiers and Perspectives. by Apostolopoulos V, Bojarska J, Chai TT, Elnagdy S, Kaczmarek K, Matsoukas J, New R, Parang K, Lopez OP, Parhiz H, Perera CO, Pickholz M, Remko M, Saviano M, Skwarczynski M, Tang Y, Wolf WM, Yoshiya T, Zabrocki J, Zielenkiewicz P, AlKhazindar M, Barriga V, Kelaidonis K, Sarasia EM, Toth I. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7830668.txt.
Introduction
Apostolopoulos and co-authors give a global review of short peptides and their medical promise. Peptides are short protein fragments. They carry signals through all forms of life. They also block or mimic protein contacts. The review marks 100 years of peptide therapy since insulin began in the 1920s.
Writers came from every continent for this survey. Early peptide drugs only replaced missing hormones. Modern ones cross cell membranes and hit inside targets. The review weighs strengths and weak points of short peptides. It covers better synthesis methods and nano delivery tricks. Computer design and smart materials feature as well. Disease uses range widely across the sections. The authors map what blocks wider use and what may clear those blocks.
Catalog record
| CREATOR | Apostolopoulos V, Bojarska J, Chai TT, Elnagdy S, Kaczmarek K, Matsoukas J, New R, Parang K, Lopez OP, Parhiz H, Perera CO, Pickholz M, Remko M, Saviano M, Skwarczynski M, Tang Y, Wolf WM, Yoshiya T, Zabrocki J, Zielenkiewicz P, AlKhazindar M, Barriga V, Kelaidonis K, Sarasia EM, Toth I. |
|---|---|
| YEAR | 2021 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 181 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
A Global Review on Short Peptides: Frontiers and Perspectives † By Vasso Apostolopoulos, Joanna Bojarska, Tsun-Thai Chai, Sherif Elnagdy, Krzysztof Kaczmarek, John Matsoukas, Roger New, Keykavous Parang, Octavio Paredes Lopez, Hamideh Parhiz, Conrad O Perera, Monica Pickholz Published in: Molecules DOI: 10.3390/molecules26020430 ABSTRACT Abstract Peptides are fragments of proteins that carry out biological functions. They act as signaling entities via all domains of life and interfere with protein-protein interactions, which are indispensable in bio-processes. Short peptides include fundamental molecular information for a prelude to the symphony of life. They have aroused considerable interest due to their unique features and great promise in innovative bio-therapies. This work focusing on the current state-of-the-art short peptide-based therapeutical developments is the first global review written by researchers from all continents, as a celebration of 100 years of peptide therapeutics since the commencement of insulin therapy in the 1920s. Peptide “drugs” initially played only the role of hormone analogs to balance disorders. Nowadays, they achieve numerous biomedical tasks, can cross membranes, or reach intracellular targets. The role of peptides in bio-processes can hardly be mimicked by other chemical substances. The article is divided into independent sections, which are related to either the progress in short peptide-based theranostics or the problems posing challenge to bio-medicine. In particular, the SWOT analysis of short peptides, their relevance in therapies of diverse diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are discussed. Keywords: short peptides, constrained amino acids and peptide (bio)mimetics, drug design and drug/gene delivery, vaccines, aptamers, cell-penetrating peptides, synthesis, SARS-COV-2, cancer, bilayer interactions, altered peptide ligands, ant/super/agonists, diketopiperazine, cosmeceuticals 1. Introduction 2. Brief History 3. Short Peptides: Definition 4. Frontiers and Prospects of Short Peptides 4.1. Advantages vs. Disadvantages: SWOT Analysis 4.2. To Overcome Shortcomings of Peptides: Mission (Im)possible? 4.2.1. Constrained Amino-Acids as a Molecular “Meccano” 4.2.2. Cyclic Peptides and Mimetics 4.2.3. Ultra-Short Peptides: Less Is More 4.2.4. Nanoengineering & a Supramolecular Approach 5. Synthesis 5.1. Advances in the Synthesis of Short Peptides and Modified Amino Acids 5.2. Short Difficult Peptide Synthesis 6. In Silico Studies 6.1. Geometry Optimization, Conformational Analysis 6.2. Modelling of Short Peptides 6.3. Peptide Interactions with Lipid Bilayers using Molecular Dynamics Simulations 7. Peptide-Based Therapies 7.1. Monocyclic, Bicyclic and Tricyclic Cell-Penetrating Peptides as Molecular Transporters 7.2. Short Peptides in Gene Delivery 7.3. Taking Peptide Aptamers to a New Level 7.4. Peptide-Based Vaccines 7.5. The Role of Short Peptides in Neurodegenerative Therapy 7.6. Immune Modulation Using Altered Peptide Ligands in Autoimmune Diseases 7.7. Relevance of Short Peptides in Stem Cell Research 7.8. Short Peptide-Based Anti-Viral Agents against SARS-CoV-2 7.9. Antimicrobial Lactoferrin-Based Peptides as Anti-COVID-19 7.10. Peptides from Digestion of Proteins 7.11. Nutraceuticals 7.12. Marine Peptides 7.13. Peptide-Based Cosmeceuticals 1. INTRODUCTION Recently, short peptides have attracted increasing attention in biology, chemistry, and medicine due to their specific features. They are appreciated as novel and more efficient therapeutical agents with reduced side effects. Their structural diversity combined with the conformational flexibility is used to control interactions with particular receptor sites. Peptides display high selectivity due to specific interactions with their targets. Moreover, the number of short peptides involved in important biological processes is steadily growing by far exceeding that resulting from the traditional mimetic approach. Unfortunately, peptides also have profound medical limitations, namely the development of oral peptide-based therapeuticals that modulate cellular processes via high affinity binding is like a search for the Holy Grail [1]. This critical review is written by a broad, multidisciplinary group of leading scientists, experts in the field from academia and pharmacy from all continents of the world providing a priceless global point of view on short peptides towards biomedical innovations. It is compiled as a holistic story from very simple bio-molecules to next-generation advanced theranostics in diverse, multidirectional scenarios. More specifically, the advantages vs. disadvantages of short peptides, their relevance in therapies of a wide range of diseases, improvements in (bio)synthesis platforms, advanced nano-supramolecular technologies, aptamers, altered peptide ligands and in silico methodologies to overcome peptide limitations, modern smart bio-functional materials, vaccines, and drug/gene-targeted delivery systems are considered. It gains unequaled insight into the world of functional biologically active peptides either accessible from nature’s repertoire or synthetic species. Short peptides, as fragments of proteins, have become intriguing agents of almost unlimited possibilities, which are awaiting further exploitation in the near future. We profoundly believe that these simple bio-molecules will open up whole new vistas, offering promising solutions in shaping the future novel bio-medicine. 2. BRIEF HISTORY In 1902, two distinguished German chemists, Hermann Emil Fischer and Franz Hofmeister, proposed that proteins are constituted by amino acids linked by bonds between the amino group of the proceeding amino acid and the carboxyl group of the following residue [2]. However, proteins were initially characterized by the Dutch chemist Gerardus Johannes Mulder, but their name was coined out by the Swedish chemist Jöns Jacob Berzelius, in 1838 [3,4]. The term “protein” is derived from the “proteios” (“primary”) i.e., representing the first position in living organisms [4,5,6]. Nevertheless, proteins do not exist without peptides. A name “peptide” comes from “peptós” (in Greek “digested, digestible”) and reflects the fact that peptides are generated by the proteolytic cleavage reaction. The first peptides and amino acids were discovered at the beginning of 19th century [7,8]. The first amino acid, asparagine, was isolated from asparagus by French chemists Louis-Nicolas Vauquelin and Pierre Jean Robiquet in 1806 [9,10]. Their chemical category was recognized by the French Charles Adolphe Wurtz, in 1865, but the expression “amino acid” was used for the first time in 1894, in German as Aminosäure [11,12]. Interestingly, the first peptide, benzoylglycylglycine, was synthesized by the German chemist Theodor Curtius, in 1881 [13]. However, a more efficient synthesis was described by Fischer and the French chemist Ernest Fourneau in 1901 [14,15]. In consequence, Fisher is known as the “father” of peptide chemistry [16]. Peptides exist in all terrestrial living organisms and are indivisibly related to the origin of life [17]. Cooperative interactions among peptides and other molecules (amino acids, proteins, nucleic acids, lipids) were the driving forces at all stages of chemical evolution [18]. Nowadays, a chemical peptide synthetic biology approach facilitates theories on the creation of life, in particular in the eyes of scientists who believe that historically chemistry proceeds biology [19,20,21]. 3. SHORT PEPTIDES: DEFINITION In general, a peptide consists of at least two amino acids. An oligopeptide is a short chain of amino acids (“a few”). A polypeptide is a long chain of amino acids (“many”). Protein contains at least one polypeptide chain folded into correct shapes. There is no strict boundary between a peptide and a protein or an oligopeptide and a polypeptide other than the “size”. As stated in the International Union of Pure and Applied Chemistry (IUPAC), oligopeptides consist of fewer than about 10–20 amino acids, while polypeptides have more than 20 residues [22]. According to the biological dictionary, oligopeptides comprise about 2–40 amino acids, while the medical definition indicates a fragment of protein consisting of fewer than 25 amino acids. On the other hand, proteins, according to IUPAC can be polypeptides consisting of more than about 50 mers, but